Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02364609
Title Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, Davis
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field